分子生物学因子联合检测判断Ⅰ期肺腺癌预后的研究

Molecular biological markers for prognosis of stageⅠadenocarcinoma of lung

目的通过对Ⅰ期肺腺癌患者的一系列分子生物学标记物的评估,找出有判断预后价值的分子生物学指标。方法应用免疫组化方法检测68例Ⅰ期肺腺癌术后癌组织中Ki-67、Her-2、P16、p53、VEGF、MMP-9和CD44v6的表达情况。用COX相对危险回归法分析这些因子的表达情况与患者预后的关系。结果多因素分析表明以下分子标记物的表达与患者不良预后有显著相关性:p53(RR=3.228,p=0.010);MMP-9(RR=2.071,p=0.033);VEGF(RR=2.577,p=0.025)。结论p53、VEGF、MMP-9对Ⅰ期肺腺癌患者的预后判断有重要价值,多因子联合检测更有意义。

Objective To find out the prognostic value of each marker through evaluating a panel of molecular biological markers in patients with stage [ lung adenocarcinoma. Methods Pathologic specimens were collected from 68 patients with stage I lung adenocarcinoma. A panel of molecular markers, including Ki-67, Her-2, p16,P53, VEGF, MMP-9 and CD44v6 were chosen for immunohistochemical analysis of the tumor. Cox proportional hazards regression analysis was used to construct an independent risk model for cancer death. Results Multivariable analysis demonstrated significantly elevated risk for the following molecular markers ：p53 （ RR = 3. 228, p = 0. 010） ; MMP-9 （ RR = 2. 071, p = 0. 033 ） ;VEGF（ RR = 2. 577, p = 0-025 ）. Conclusion Our data do support the following three markers as independent predictive factors respeatively of poor outcome（ in patients with stage I adenocarcinoma of lung） ： p53, VEGF, MMP-9.